Management of Ulcerative Colitis Using Vedolizumab After Liver Transplantation for Primary Sclerosing Cholangitis

J Crohns Colitis. 2016 Feb;10(2):236. doi: 10.1093/ecco-jcc/jjv182. Epub 2015 Oct 8.

Authors

Magdalena Meszaros¹, Georges-Philippe Pageaux², Romain Altwegg²

Affiliations

¹ Unité de Transplantation Hépatique, Pôle Digestif, CHU Saint-Eloi, Montpellier, France [email protected].
² Unité de Transplantation Hépatique, Pôle Digestif, CHU Saint-Eloi, Montpellier, France Département de transplantation hépatique, Université Montpellier I, Montpellier, France.

PMID: 26449788
DOI: 10.1093/ecco-jcc/jjv182

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / administration & dosage*
Cholangitis, Sclerosing / complications
Cholangitis, Sclerosing / surgery*
Colitis, Ulcerative / complications
Colitis, Ulcerative / drug therapy*
Dose-Response Relationship, Drug
Drug Administration Schedule
Follow-Up Studies
Gastrointestinal Agents / administration & dosage
Humans
Liver Transplantation*
Male
Remission Induction

Substances

Antibodies, Monoclonal, Humanized
Gastrointestinal Agents
vedolizumab